Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that tianeptine may suppress the transition to catagen, promoting hair growth in a stress-induced alopecia areata mouse model.

This review discusses the molecular mechanisms and clinical applications of thymosin β4, highlighting its potential benefits for inflammation, wound healing, tumor metastasis, and other medical conditions but reports no new experimental results.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

This report documents a case where a man survived sub-acute toxicity from an overdose of the anticancer drug UFT due to effective treatment with antibiotics and granulocyte colony-stimulating factor.

In this study, topical tofacitinib significantly increased hair regrowth in mice compared to minoxidil or vehicle, potentially due to elevated VEGF levels and reduced inflammation.

In this study, PRP administration in rabbit tibia bones with segmental defects improved bone healing scores and advanced bone development stages compared to the control group.

This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.

In this study, researchers found that the ability of hamster polyomavirus to cause lymphoid tumors in Syrian hamsters may be linked to its association with the tyrosine kinase p59fyn.

CTP-543 is generally safe for treating alopecia areata.

This review explores the mechanisms and clinical applications of thymosin β4, highlighting its potential in various medical fields, but it presents no new research findings.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This study reported that FDG PET/CT imaging provided additional information that significantly impacted the treatment and prognosis in seven out of ten canine cancer patients, suggesting its potential in veterinary oncology.

This study highlights that variations in clinical outcome reporting can undermine the validation of NTCP models for RIA, stressing the need for a standardized and objective scoring system.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

This report describes the sonographic characteristics of a proliferating trichilemmal tumor in the subungual region, identifying it as a heterogeneous mass with echogenic foci, potentially representing keratin and cholesterol.

This case report highlights that tumid lupus erythematosus should be considered in the differential diagnosis of annular scalp lesions with non-scarring alopecia, emphasizing histopathological examination for accurate diagnosis.

This study explored the effects of various nutraceutical ingredients on breast cancer cell lines but found no conclusive information regarding their interaction with tamoxifen therapy.

In this study, researchers found that specific mutations in iRhom2 in mice lead to skin and hair abnormalities which depend on the presence of the protein ADAM17, suggesting a complex role for iRhom2 in tissue development and potential implications for treating tylosis with oesophageal cancer.

This article discusses the clinical features of tumid lupus erythematosus and emphasizes its importance as a differential diagnosis for noncicatricial alopecia, highlighting a case similar to alopecia areata without reporting new clinical results.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This study suggests that TGF-β 2 plays a critical role in hair follicle morphogenesis and may enhance the effectiveness of future cell therapies for hair regrowth using expanded dermal papilla cells.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

This case report describes two patients with ulcerative colitis and alopecia areata who did not respond to various treatments but achieved remission and improved hair growth after starting tofacitinib.

This study explored the effects of TTFE on male androgenic alopecia, finding that topical application increased hair density, follicular diameter, and scalp hydration while reducing water loss and sebum production in a 12-week trial.